Purple Biotech Ltd. (PPBT)

Market Cap	13.48M
Revenue (ttm)	n/a
Net Income (ttm)	19.88M
Shares Out	27.51M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,114
Open	0.470
Previous Close	0.453
Day's Range	0.430 - 0.490
52-Week Range	0.302 - 2.098
Beta	0.57
Analysts	Strong Buy
Price Target	10.00 (+1,940.82%)
Earnings Date	May 14, 2024

About PPBT

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin recept...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: PPBT

Analyst Forecast

According to 4 analysts, the average rating for PPBT stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 1,940.82% from the latest price.

Price Target

$10.0

(1,940.82% upside)

Analyst Consensus: Strong Buy